The 2nd Annual In-House Counsel's Forum on

Pharmaceutical Antitrust

Monday, April 24, 2006

About

Get the critical information you need to recognize and evaluate complex antitrust issues affecting the protection and exploitation of your vital pharmaceutical products.

In-house and outside counsel advising the pharmaceutical industry must have an up-to-the-minute and in-depth understanding of the antitrust issues which affect many important legal and business decisions directly related to maximizing the profitability of their pharmaceutical patents.

The importance of being able to recognize and effectively address these issues is greater than ever as federal and state regulators, as well as competitors and the plaintiffs' class action bar, continue to closely scrutinize every action that could be considered anticompetitive at nearly every stage of a drug's development and life cycle. Failure to understand and evaluate your options can result in expensive and time-consuming repercussions down the road.

To help you navigate these potential pitfalls, American Conference Institute has developed the In-House Counsel's Forum on Pharmaceutical Antitrust publication to provide you with the tools you need to develop practical defensive and offensive strategies for dealing with antitrust issues in connection with your pharmaceutical products.

This publication brings together the comprehensive materials from an expert faculty of leading pharmaceutical in-house counsel, government regulators, and expert antitrust attorneys who will give you practical advice on overcoming some of the biggest antitrust challenges facing pharmaceutical companies, as well as insights into compliance hotspots on the horizon, including:

  • Extending your brand without running afoul of antitrust regulation
  • Structuring brand/generic and generic/generic alliances and licenses
  • Navigating supply and distribution complexities
  • Avoiding antitrust violations in your in-licensing, co-marketing and co-promotion transactions
  • Ensuring potential antitrust objections do not frustrate your planned merger or acquisition
  • Deciding whether (and how) to initiate or settle litigation
  • Understanding and complying with relevant international antitrust laws

Contents & Contributors

About

Get the critical information you need to recognize and evaluate complex antitrust issues affecting the protection and exploitation of your vital pharmaceutical products.

In-house and outside counsel advising the pharmaceutical industry must have an up-to-the-minute and in-depth understanding of the antitrust issues which affect many important legal and business decisions directly related to maximizing the profitability of their pharmaceutical patents.

The importance of being able to recognize and effectively address these issues is greater than ever as federal and state regulators, as well as competitors and the plaintiffs' class action bar, continue to closely scrutinize every action that could be considered anticompetitive at nearly every stage of a drug's development and life cycle. Failure to understand and evaluate your options can result in expensive and time-consuming repercussions down the road.

To help you navigate these potential pitfalls, American Conference Institute has developed the In-House Counsel's Forum on Pharmaceutical Antitrust publication to provide you with the tools you need to develop practical defensive and offensive strategies for dealing with antitrust issues in connection with your pharmaceutical products.

This publication brings together the comprehensive materials from an expert faculty of leading pharmaceutical in-house counsel, government regulators, and expert antitrust attorneys who will give you practical advice on overcoming some of the biggest antitrust challenges facing pharmaceutical companies, as well as insights into compliance hotspots on the horizon, including:

  • Extending your brand without running afoul of antitrust regulation
  • Structuring brand/generic and generic/generic alliances and licenses
  • Navigating supply and distribution complexities
  • Avoiding antitrust violations in your in-licensing, co-marketing and co-promotion transactions
  • Ensuring potential antitrust objections do not frustrate your planned merger or acquisition
  • Deciding whether (and how) to initiate or settle litigation
  • Understanding and complying with relevant international antitrust laws

Contents & Contributors


MAXIMIZING LIFECYCLES - MINIMIZING ANTITRUST RISK
Ann Rappleye, Wyeth
Cathy Hoffman, Arnold & Porter LLP

STATE ANTITRUST ENFORCEMENT IN THE PHARMACEUTICAL INDUSTRY
Meredyth Smith Andrus, Office of the Maryland Attorney General

AUTHORIZED GENERICS: WINDFALL TO CONSUMERS OR NEW STRATEGY TO HARM COMPETITION?
David Balto, Robinds, Kaplan, Miller & Ciresi LLP

KNOWING THE BOUNDARIES WHEN SETTLING PHARMACEUTICAL DISPUTES
William M. Rubenstein, Axinn, Veltrop & Harkrider LLP

PHARMACEUTICAL INDUSTRY MERGERS, STRATEGIC ALLIANCES, AND JOINT VENTURES
Michael R. Moiseyev, Federal Trade Commission
Marc Brotman, Pfizer, Inc. Stephen A. Stack, Jr., Dechert LLP

THE ROBINSON PATMAN ACT AND REEDER-SIMCO
Stephen J. Cipolla, Merck & Co., Inc.

PHARMACEUTICAL PRICING ATTORNEY GNEERAL'S PERSPECTIVE
James A. Donahue, III, Office of the Attorney General of Pennsylvania

PARALLEL TRADE IN PHARMACEUTICAL PRODUCTS IN EUROPE: EU COMPETITION ISSUES
David Hull, Covington & Burling

STRUCTURING PROFITABLE IN-LICENSING, CO-DEVELOPMENT, AND CO-PROMOTION AGREEMENTS THAT WILL WITHSTAND ANTITRUST SCRUTINY
Thomas J. Horton, Thelen Reid & Priest LLP



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0